Sun Pharma to partner with ICGEB to develop novel Dengue treatment
pharmafile | May 4, 2016 | News story | Research and Development | Dengue fever, Sun Pharma, collaboration, dengue, development, drug, icgeb, international centre for genetic engineering and biotechnology, partnership, sun pharmaceutical
Sun Pharmaceuticals (BSE: 85715) and the International Centre for Genetic Engineering and Biotechnology (ICGEB) are set to team up to develop a novel botanical drug for the treatment of dengue.
The agreement will see the development of Cipa (ciassampelos pariera) with Sun granted access to all the intellectual properties of this drug cross 17 countries. ICGEB will establish assay systems for the development of Cipa and work exclusively with Sun on clinical treatment strategies based on botanical and phyto-pharmaceuticals. While Sun has indicated the payment of royalties post-publication, no other financial details have been disclosed.
India represents 50% of the global population said to be at risk of dengue. Severe forms of the disease can be potentially fatal, and this plant-derived treatment will aim to inhibit the replication of the virus in living cells.
Kirti Ganorkar, senior VP of business development at Sun, says: “Dengue poses a significant global public health risk. In tropical countries like India where dengue outbreaks are significantly intense, a drug for dengue is recognised as an unmet public health need. Our partnership with ICGEB aims to develop Cipa as a safe, effective and affordable botanical drug for treatment of dengue.”
Dr Dinakar Salunke, director of the ICGEB in New Dehli, comments: “Using the knowledge of traditional Indian medicine, we explored the indigenous herbal bio-resource to identify plants with pan-DENV inhibitory activity and identified Cipa as a safe, affordable and effective solution.”
Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz …
Halozyme Therapeutics has announced a global collaboration and non-exclusive license with Acumen Pharmaceuticals, providing Acumen …